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Peroxisome proliferator-activated receptors (PPARs) are members of a steroid hormone receptor superfamily that responds to
changes in lipid and glucose homeostasis. Peroxisomal proliferator-activated receptor subtype γ (PPARγ)h a sr e c e i v e dm u c h
attention as the target for antidiabetic drugs, as well as its role in responding to endogenous compounds such as prostaglandin J2.
However, thiazolidinediones (TZDs), the synthetic agonists of the PPARγ are tightly associated with ﬂuid retention and edema,
as potentially serious side eﬀects. The epithelial sodium channel (ENaC) represents the rate limiting step for sodium absorption
in the renal collecting duct. Consequently, ENaC is a central eﬀector impacting systemic blood volume and pressure. The role of
PPARγ agonists on ENaC activity remains controversial. While PPARγ agonists were shown to stimulate ENaC-mediated renal
salt absorption, probably via Serum- and Glucocorticoid-Regulated Kinase 1 (SGK1), other studies reported that PPARγ agonist-
induced ﬂuid retention is independent of ENaC activity. The current paper provides new insights into the control and function
of ENaC and ENaC-mediated sodium transport as well as several other epithelial channels/transporters by PPARs and particularly
PPARγ. The potential contribution of arachidonic acid (AA) metabolites in PPAR-dependent mechanisms is also discussed.
1.Introduction
Peroxisome proliferator-activated receptors (PPARs) are
ligand-activated transcription factors belonging to a nuclear
hormone receptor superfamily containing three isoforms
(alpha, beta/delta, and gamma). The name peroxisome
proliferator-activated receptor derives from the ability of the
ﬁrst member of the family identiﬁed, PPARα,t or e s p o n d
to various compounds that induce peroxisome proliferation.
This function is not shared by other members of the PPAR
family. Instead, they have emerged as major regulators of
various aspects of lipid metabolism and metabolic control
[1–3].PPAR-β/δ (NR1C2)isubiquitouslyexpressedinmany
tissues, especially in the brain; however, its function has yet
to be clearly deﬁned.
This paper will focus on two isoforms: PPARγ and
to less extent PPARα. Their role has been increasingly
recognized to be important in hypertension, metabolic
disorders and cardiovascular diseases. Furthermore nuclear
receptors including PPARγ are promising targets for drug
development. Functioning as transcription factors they
control cellular processes at the level of gene expression.
Their modulation of nuclear receptor activity produces
selective alterations in downstream gene expression. PPARs
regulate gene transcription by two mechanisms: (1) trans-
activation, a DNA-dependent mechanism, which involves
binding to PPAR response elements (PPRE) of target genes
and heterodimerization with the retinoid X receptor (RXR);
(2) transrepression, a process that may explain the con-
tradictory of actions of PPARs. Transrepression involves
interfering with other transcription-factor pathways in a
DNA-independent way [1].
Various fatty acids serve as endogenous ligands for
PPARs: prostaglandin J2 is an endogenous PPARγ ligand,2 PPAR Research
whereas PPARα is activated by cytokines. After ligand
binding, PPARs undergo speciﬁc conformational changes
that allow for the recruitment of one coactivator protein or
more. PPARs function as an obligate heterodimer with RXRs
and recognize PPRE located in the promoter region of target
genes[4].Inaddition, PPARactivatorswereshowntoinhibit
the activation of inﬂammatory response genes by negatively
interfering with the nuclear factor-κB( N F - κB), STAT and
AP-1signalingpathways[5].Thesecharacteristics,combined
withPPARsinvolvementinsigniﬁcantdiseases,makenuclear
receptors a key target for the development of disease-speciﬁc
therapies.
2. PPARs andTheir Role in Hypertension
andFluid Retention
Insulin-sensitizing drugs thiazolidinediones (TZDs) are
known as PPARγ-agonists, and hypolipidemic drugs ﬁbrates
are known as PPARα ligands. Agonists of PPARγ and PPARα
are currently approved for use in treating type 2 diabetes and
dyslipidemia, respectively.
PPARα is expressed predominantly in the liver, heart,
muscle, and vascular wall. Sato and colleagues generated
isoform-speciﬁc anti-PPAR antibodies to determine the
localization of these proteins in the rat kidney [6]. Regarding
PPARα, it was widely expressed along the nephron segments
(proximal and distal tubules, the loop of Henle, and
medullary collecting ducts) glomeruli, and intima/media of
renal vasculatures. Previous studies reported that PPARα
expression was mainly localized to the proximal tubules
[7–9]. Based on the prominent distribution of PPARα in
the kidney, PPARα is likely to aﬀect renal salt transport.
However, it is important to note that tissue expression of
all three PPAR isoforms is likely to vary under diﬀering
physiological and/or pathological conditions.
Interestingly, studies using PPARα−/− mice have pro-
duced conﬂicting ﬁndings in regard to its role in blood
pressure regulation [10]. Deletion of PPARα has been
shown to signiﬁcantly increase [11], decrease [12]a n d
have no signiﬁcant eﬀect [13] on systolic blood pressure
compared with wild-type controls. Further studies sug-
gest that PPARα participates in pressure natriuresis and
aﬀects Na+ transport via amiloride- and thiazide-sensitive
mechanisms. Despite defective fatty acid oxidation, PPARα
null mice are not hypertensive but develop salt-sensitive
hypertension [14]. The observation that cloﬁbrate improved
pressure natriuresis [15]a n dP P A R α activation inhibited
ion transport in the isolated proximal tubules [16], gives
credence to the notion that PPARα may be involved in the
salutary eﬀects of the kidney. However, a role of PPARα in
ENaC-mediated sodium reabsorption is still unclear.
Troglitazone was the ﬁrst TZD which was approved
in January 1997 as a glucose-lowering therapy because it
enhances insulin sensitivity in patients with type 2 diabetes
[17]. Due to hepatotoxicity, it has since been replaced by
PPARγ-agonistsrosiglitazoneandpioglitazone[1].However,
both rosiglitazone and pioglitazone have been associated
with increased development of edema in clinical trials.
Non-insulin-dependent diabetes mellitus with associated
insulin insensitivity and reactive hyperinsulinemia is often
complicatedbyhypertension.Increasedbloodpressurecould
in part be due to volume expansion resulting from improper
avid Na+ reabsorption by the kidney. Insulin increases Na+
reabsorption in the distal renal nephron; likely by targeting
ENaC localized to the luminal membrane of principal cells.
The highest incidence of edema has been reported when
TZDs are utilized in combination with insulin.
In addition to peripheral edema, reports have described
pulmonary edema and heart failure associated with thiazo-
lidinedione therapy. In all such reports, patients failed to
respond to diuretics during use of TZDs. Clinical improve-
ment ensued only after discontinuation of TZD therapy
[18, 19]. A water-electrolyte imbalance observed in these
patients led researchers to investigate PPARs participation
in kidney function. Laboratory studies have demonstrated
that rosiglitazone treatment does not aﬀect blood pressure
or angiotensin-II (Ang II) production by mesangial cells
and plays a renoprotective role in Sprague-Dawley rats
[20]. Moreover, TZDs normalized expression of angiotensin
converting enzyme-1 in obese Zucker rats as well as lowered
bloodpressureandangiotensin-IIsynthesisinspontaneously
hypertensive rats on a high-salt diet with glycerol-induced
acute renal failure [21, 22].
It has been proposed that TZDs may be useful in the pre-
vention and/or treatment of hypertension, particularly when
it is associated with insulin resistance or diabetes mellitus.
TZDs attenuate the development of hypertension, normalize
cellgrowth, and improve endothelial dysfunction induced by
(Ang II). In addition TZDs prevented upregulation of Ang
II type 1 receptors, cell cycle proteins, and proinﬂammatory
mediators [23]. It has been suggested that the apparent
hypotensive eﬀects of PPARγ agonists in this model may
result from down regulation of the Ang II type 1 receptor
[10, 24]. Moreover, PPARγ was identiﬁed as an intracellular
mediator involved in the upregulation of renin transcription
[25]. Using PPARγ-knockdown in juxtaglomerular cells
(RC-PPARγﬂ/ﬂmice),increasedreninproductionwasfound
even though arterial pressure was indistinguishable in these
mice compared to wild-type animals [26].
Mouse models that disrupt PPARγ speciﬁcally in the col-
lecting ducts (CDs) in the kidney have been used to evaluate
ar o l eo fP P A R γ in ﬂuid retention. Guan et al. demonstrated
that deletion of CD PPARγ decreased renal Na+ avidity
and increased plasma aldosterone. Mice treated with TZDs
experience early weight gain from increased total body
water. Moreover, weight gain was blocked by the diuretic
amiloride [27]. Similarly, Zhang et al. found that mice
with CD-speciﬁc knockout of PPARγ were resistant to the
rosiglitazone-induced increase in body weight and plasma
volume expansion found in control mice expressing PPARγ
in the CD [28]. The role of PPARγ in regulation of sodium
transport in the kidney will be further discussed below.
3.PPARs and ArachidonicAcid Metabolites
Natural and synthetic ligands bind to PPARs, resulting in a
conformational change and activation of PPAR. The identityPPAR Research 3
of the biological ligands for PPARs remains unresolved and
is an area of active investigation. The PGD2 metabolite,
15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), was the ﬁrst
endogenous ligand for PPARγ to be discovered. Although
15d-PGJ2 is the most potent natural ligand of PPARγ, the
extent to which its eﬀects are mediated through PPARγ in
vivo remains to be determined. It is unlikely that 15d-PGJ2
i sp r e s e n ta ts u ﬃcient levels in vivo to be a biologically
signiﬁcant PPAR ligand. Furthermore, it is possible that
ligands for PPARs have diﬀerent potency and eﬃcacy and
may be distinct in diﬀerent tissues.
The function of PPARs is modiﬁed by the precise shape
of their ligand-binding domain; which is induced by ligand
binding as well as a number of coactivators and corepressor
proteins. It is well known that endogenous ligands for the
PPARγ includefreefattyacidsandeicosanoids.Furthermore,
the localization of CYP4A and PPARγ proteins as well
as the inducibility of Cyp4A expression and activity by
PPARγ agonists have been determined in the rat kidney
[29]. Moreover, the eﬀect of PPARγ agonists on the Cyp4A
pathway was recently demonstrated and provided experi-
mental evidence that pioglitazone down regulates Cyp4A
leading to sodium retention [30]. Treatment of hypertensive
Cyp4a10(-/-) mice with Wyeth 14,643, (a selective PPARα
ligand), up-regulated renal Cyp2c44 expression, increased
urine epoxyeicosatrienoic acid (EET) concentrations, and
normalized the animals systemic blood pressure [31, 32].
Thus, it is possible that eicosanoids and free fatty acids might
be involved in PPARs-regulated changes in ﬂuid retention.
Multiple factors are presumed to regulate renal sodium
handling including the renin-angiotensin system (RAS),
nitric oxide (NO), and prostaglandins. Recent studies have
demonstrated that PPARγ ligands enhance NO production
through the increased expressions of NO synthase (NOS) in
the kidneys of obese rats, thus shifting the sodium balance
to increased excretion [33]. In addition, PPARγ is reported
to induce cyclooxygenase-2 (COX-2), an enzyme producing
PGE2 and PGI2 in several cell lines [34], which also could
favor sodium excretion.
Arachidonic acid (AA) is primarily metabolized by
cyto-chrome P-450 (CYP) enzymes to 19- and 20-hydrox-
yeicosatetraenoic acids (19- and 20-HETE) and EETs (5,6-,
8,9-, 11,12-, and 14,15-EET) and these compounds play
critical roles in the regulation of renal, pulmonary and
cardiac function [35]. The expression of CYP 4A (CYP4A)
isoform was determined in cortical collecting ducts (CCDs)
[36]. Similarly, Cyp2C isoforms are expressed in the CCD
[37–39]. It was previously shown that AA signiﬁcantly
decreases ENaC activity in CCD cells. Adenosine inhibits
ENaC activity by stimulation of the A1 adenosine receptor
in the CCD and the eﬀect of adenosine is mediated by
11,12-EET [38, 40, 41]. 11,12-EET has also been shown
to mediate AA-induced inhibition of 18pS basolateral K+
channels [42] and activation of BK channels in the apical
membraneoftheCCD[39].20-HETEandEET sha v eactions
on the thick ascending limb (TAL) cells that would decrease
sodium reabsorption. 20-HETE production is involved in
reducing the activity of the apical 70pSK+ channels in
the medullary TAL (mTAL) [43, 44]. AA inhibits 50pS K+
channels in the basolateral membrane of the mTAL mainly
through CYP-dependent metabolities of AA [45]. Recently
it was demonstrated that AA inhibits the 10pS chloride
channel in the basolateral membrane of the mTAL and that
the eﬀect is mediated by 20-HETE [46]. Thus, AA and its
metabolites are involved in the regulation of various ion
channels in the kidney. Moreover, a dysfunctional Cyp4a10
genecausesatypeofhypertensionthatisdietarysaltsensitive
and associated with alterations in the gating activity of ENaC
[31]. The above observations allow the speculation that
TZDs might suppress speciﬁc AA metabolite production,
therefore reducing sodium excretion.
4.PPARs and ENaC
The regulation of sodium reabsorption is one of the most
important questions in the area of kidney physiology. ENaC
represents the rate limiting step for Na+-reabsorption across
many epithelia, including those in the distal nephron, lungs
and colon, and as such plays a central role in salt homeostasis
and blood pressure control [47, 48]. ENaC-mediated sodium
transport plays a pivotal role in homeostasis of epithelial
kidney tissues and other organs. Abnormalities in ENaC
function have been linked to disorders of total body Na+
homeostasis, blood volume, blood pressure, and lung ﬂuid
balance [49, 50]. Despite several reports testing regulation of
ENaC by PPARγ, the role of PPARγ to regulate ENaC has not
yet been fully resolved and remains controversial. Here, we
summarize the current knowledge regarding involvement of
PPARs in regulation of this channel.
Guan et al. found that treatment with rosiglitazone and
pioglitazone causes body ﬂuid accumulation in C57BL/6J
mice within a span of days. Pretreatment of mice with
amiloride, a selective inhibitor of ENaC, completely blocked
weightgainproducedbysubsequenttreatmentwithpioglita-
zone. To establish whether CD PPARγ expression is required
for TZD-associated weight gain, mice were generated that
selectively lack PPARγ in their CDs. This deletion pre-
vented pioglitazone-induced ﬂuid retention, decreased renal
Na+ avidity and increased plasma aldosterone. Treating
cultured CDs with TZDs increased amiloride-sensitive Na+
absorption and Scnn1g mRNA (encoding ENaC γ-subunit)
expression through a PPARγ-dependent pathway [27]. Inde-
pendently, Zhang and colleagues showed that CD-speciﬁc
deletion of PPARγ blocks TZD-induced ﬂuid retention in
mice and that rosiglitazone stimulated sodium transport
in primary cultures of CDs cells expressing PPARγ but
not in cells lacking this receptor [28]. Plasma volume
expansion, decreased urine volume and sodium excretion
werealsoobservedinSprague-DawleyratstreatedwithTZDs
rosiglitazone and farglitazar [51, 52].
It was proposed that PPARγ activators may increase
renal Na+ reabsorption by stimulating ENaC and Serum-
and Glucocorticoid-Regulated Kinase 1 (SGK1). The CCD
is the major segment mediating the sodium-retaining
eﬀects of aldosterone, primarily through the upregulation
of ENaC activity. The early eﬀect of aldosterone on ENaC-α
translocation is believed to be regulated by SGK1; as SGK1
expression is rapidly induced by aldosterone and strongly4 PPAR Research
stimulates ENaC activity [54, 55]. PPARγ is abundant in
native CCD [9]. PPARγ is also highly expressed in human
renal CCD [56], the A6, M1 and mpkCCDc14 cells [57].
Splice variants of the human PPARγ (PPAR-γ1 and PPAR-γ2)
have been identiﬁed [58]. It was shown that PPAR-γ1,b u t
not PPAR-γ2, was expressed along the nephron segments
predominantly in the cortex [6].
Hong et al.have previouslyshown thatSGK1 activity in a
human CCD cell line is stimulated by treatment with PPARγ
agonists. These changes are paralleled by an increase in
SGK1 mRNA which may be abolished by pretreatment with
as p e c i ﬁ cP P A R γ antagonist. An increase in SGK1 mRNA
may also lead to increased levels of cell surface ENaCα [56].
PPARγ agonists have been proposed to increase renal Na+
reabsorption by stimulating SGK1 and ENaC [59]. Artunc
et al. also have demonstrated that SGK1 contributes to the
volume retention during treatment with pioglitazone using
mice lacking SGK1 (sgk1–/–); however, SGK1 did not fully
account for this eﬀect [54].
Increasing evidence suggest that PPARγ agonists do not
directly alter ENaC activity or ENaC-mediated sodium reab-
sorption. Nofziger et al. ﬁrst demonstrated that activation of
PPARγ with either pioglitazone or the more potent GW7845
does not directly enhance basal or insulin-stimulated Na+
transport via ENaC in the A6, M-1 or mpkCCDc14 cell
lines. No change in SGK1 expression levels were found
in mpkCCDc14 cells after 18–24hrs treatment with PPARγ
agonists [57]. Similar to this study, we demonstrated no
changes or even a slight decrease in basal sodium or insulin-
stimulated reabsorption in mpkCCDc14 cells in response to
diﬀerent PPARγ agonists including: pioglitazone, rosiglita-
zone, troglitazone and 15d-PGJ2. Moreover rosiglitazone has
no eﬀect on ENaC current density when the channel was
reconstituted in CHO cells [53]. Wilson and colleagues have
also recently conﬁrmed our observations that rosiglitazone
and pioglitazone had no discernible eﬀect on transepithelial
Na+ absorption in unstimulated or insulin-stimulated distal
nephron cells and distal airway epithelial cells. Both TZDs
also failed to alter cellular SGK1 activity [60].
Furthermore, Vallon and colleagues utilized mice with
conditionally inactivated α-ENaC (Scnn1aloxloxCre)i nC D s
to test the role of ENaC in TZD-induced ﬂuid retention.
Interestingly, increased body weight, plasma volume, and
ﬂuid content of abdominal fat pads were observed both
in control (Scnn1aloxlox) and Scnn1aloxloxCre animals after
rosiglitazone treatment. However, the treatment did not
signiﬁcantly alter the renal expression of ENaC subunits
or Na-Cl cotransporter (NCC) in both mouse lines [61].
Similar, Khan et al. had earlier also demonstrated that renal
cortical abundance of NCC was not signiﬁcantly changed in
obeseZuckerratsafterrosiglitazonetreatment[62].Vallonet
al. proposed that TZDs-induced ﬂuid retention and weight
gain are mediated by nonselective cation channels (NSC)
in inner medullary CD (IMCD) and ENaC-mediated Na+
reabsorption in CDs is not critical for this eﬀect. According
to single-channel data, a TZD diet did not aﬀect ENaC
activity in freshly isolated CCDs of wild-type mice [61].
These data strongly argue against a primary and critical
role of ENaC in TZD-induced ﬂuid retention. On the other
hand, this study does not explain TZD-dependent increase
of γ-ENaC mRNA expression [27] or cell surface expression
measured with cell surface biotinylation of α-ENaC after
4hrsandα-ENaC mRNA after 24hrs treatment with TZDs
in human CCD [56]. Furthermore, as proposed by Rubera
et al., CD-speciﬁc inactivation of α-ENaC does not impair
sodium balance [63]. When α-ENaC expression was deleted
selectively from the CDs, leaving intact ENaC expression in
the renal connecting tubule and nonrenal tissues, the mice
were viable and exhibited only a very mild phenotype with
little or no inability to maintain ﬂuid homeostasis in the face
of salt or water restriction [63].
Our recent ﬁndings have shown that two PPARγ
antagonists, T0070907 and to a lesser extent GW9662,
decreaseNa+ reabsorptionacrossmpkCCDc14 principalcells.
Furthermore, pretreatment of monolayers with T0070907
diminished the insulin-stimulated sodium transport. Coex-
pression of PPARγ1 enhances ENaC activity when all three
channel subunits and PPARγ1 are reconstituted in CHO cells
(Figure 1)[ 53]. Thus, our data using PPARγ antagonists are
consistent with the idea that PPARγ activity is important for
maintaining basal and insulin-dependent transepithelial Na+
transport and ENaC activity.
There are no studies showing acute eﬀect of TZDs
on ENaC-mediated sodium reabsorption. Thus, most likely
TZDs aﬀect epithelial transport through only genomic
mechanisms. In transrepression, PPARγ can repress gene
transcription by negatively interfering with other signal-
transduction pathways, such as NF-κB signaling pathway, in
a DNA-binding-independent manner [1]. The RXR is the
required heterodimer partner of PPARs. It was previously
shown that RXRα mRNA was present predominately in
proximal convoluted tubule (PCT) and IMCD, whereas
RXRβ was present in all nephron segments examined except
mTAL [9]. RXR, which interacts with the PPARs, is activated
by 9-cis retinoic acid. When combined as a PPAR:RXR
heterodimer, the PPAR ligands and 9-cis retinoic acid act
synergistically on PPAR responses. It is still not clear whether
TZDs regulate ENaC activity and ENaC-mediated sodium
transport in the presence of 9-cis retinoic acid.
To date there are no reports for the involvement of
PPARα in regulation of ENaC activity. Our recent investiga-
tion surprisingly revealed a suppressive inﬂuence of PPARα
on amiloride-sensitive current density when coexpressed
with ENaC subunits in CHO cells (Figure 2). Figure 2(a)
shows overlays of ENaC currents from typical whole cell
voltageclampexperimentselicitedbystandardvoltageramps
before and after amiloride (10μM). Currents are from cells
expressingallthreemouseENaCsubunits(0.3μgeach)alone
or coexpressed with PPARα (1μg). Whole-cell macroscopic
current recordings of ENaC reconstituted in CHO cells
were made under voltage-clamp conditions using standard
methods [64–66]. Co-expression of PPARα together with
ENaC signiﬁcantly decreased amiloride-sensitive current
density from 281 ± 50 to 129 ± 26pA/pF (Figure 2(b)).
Although these data provide initial evidence it is not
clear how PPARα is involved in regulation of ENaC and
ENaC-mediated sodium transport and requires additional
investigations.PPAR Research 5
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Figure 1: Eﬀect of PPARγ antagonists on amiloride-sensitive current. (a) Time course of decreases in relative Na+ transport in response to
PPARγ inhibition with GW9662 (10μM). mpkCCDc14 cells were serum-starved overnight. PPARγ antagonist (circles) and vehicle (squares)
were added at time 0 and current was normalized to starting level. Amiloride (10μM; arrow) was added to the apical membrane at the end of
experiment. The numbers of experiments are 24 and 26 for GW9662 and vehicle, respectively. (b) Summary graph of ENaC current density
in CHO cells expressing mENaC subunits alone or coexpressed with PPARγ1 in the absence and presence of pretreatment with GW9662 (1
and10μM).Thenumberofexperimentsisshown.
∗P <. 05,versusmENaCalone;
∗∗P <. 05,versusmENaC+PPARγ1.(c)Timecoursefor
T0070907-dependentdecreasesinrelativeNa+ transportacrossmonolayersofmpkCCDc14 principalcells.Thenumbersofexperimentsare9
and 6 for control and cells treated with T0070907 (50μM), respectively. All other conditions are the same as in (a). Some results represented
here were previously published in a diﬀerent format [53].
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Figure 2: PPARα inhibits ENaC when overexpressed in CHO cells. (a) Overlays of typical macroscopic current traces before (arrow)a n d
after 10μM amiloride from voltage-clamped CHO cells transfected with mENaC alone (top)a n dw i t hP P A R α. Currents were elicited by
voltage ramping from 60mV down to −100mV (holding potential is 40mV). (b) Summary graph of ENaC activity in CHO cells when all
three mENaC subunits are expressed in the absence and presence of PPARα. The numbers of experiments are 9 and 7 for control and cells
overexpressed with PPARα cDNA (1μg), respectively.
To place these observations in the context with those
previously reported by others, our results appear to be most
supportive of the idea that ENaC is involved in PPARγ-
regulated changes in ﬂuid retention. However, possible
mechanisms underlining the regulation of ENaC via PPARγ
remain obscure and require additional studies. Furthermore,
thepotentialroleofPPARαandRXRinregulationofsodium
transport needs to be clariﬁed.
5. Other Targets of PPAR
Several additional studies argue against the notion that
TZD-induced edema formation in CCDs is due to direct
renal salt and water retention. Consequently, several mech-
anisms have been proposed. As discussed above, patch-
c l a m ps t u d i e si np r i m a r ym o u s eI M C Dc e l l sd e t e c t e da
NSC that was upregulated by pioglitazone [61]. Moreover,
electrophysiological studies of cultured IMCD cells recently6 PPAR Research
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Figure 3: Schematic illustration of the proposed role for PPARγ in the renal collecting duct. PPARγ activation by TZDs or endogenous
ligands regulate various epithelial channels/transporters including: (1) epithelial Na+ channel (ENaC) either directly or via the Serum- and
Glucocorticoid-Regulated Kinase 1 (SGK1); (2) cystic ﬁbrosis transmembrane regulator (CFTR); and (3) AQP water channels. Involvement
of PPARγ in the control of ROMK K
+ and CLC Cl− channels is still unclear. Furthermore, role of PPARγ in the regulation of paracellular
transport, and Na-K-ATPase is also proposed (not shown on this scheme).
revealed that following exposure to rosiglitazone, amiloride-
sensitive short-circuit current was unchanged at 24hrs but
was signiﬁcantly decreased at 48hrs. Along this line mRNA
expression of all three ENaC subunits exhibited a trend
of reduction at 24hrs and a nearly 50% reduction at
48hrs. Despite ENaC inhibition, transepithelial resistance
was signiﬁcantly reduced, suggesting an alternative route of
increased ion transport. However, this eﬀect was blunted in
theIMCDcellsderivedfrommicelackingPPARγ.I thasbeen
proposed that rosiglitazone-treatment of primary IMCD cell
monolayers exhibit increased paracellular Cl− ﬂux, and to a
lesser extent, paracellular Na+ ﬂux [67].
In addition various epithelial transport proteins may
contribute to TZD-induced reabsorption in the nephron.
The proximal tubule is known to mediate more than half of
total tubular sodium and water reabsorption [68]. Saad and
others have recently shown that PPARγ agonists enhance the
expression of NHE3 (Na+/H+ exchanger), AQP1 and AQP7
water channels in human proximal tubule cells through
SGK1-dependent pathways [69]. Song and colleagues
noticed that rosiglitazone increased whole kidney protein
abundance of the α-1 subunit of Na+/K+-ATPase, Na-K-2Cl
contransporter (NKCC2), NHE3, AQP 2 and 3, and NOS
[51].
Several investigations have focused on the role of PPARγ
as a regulator of chloride transport through cAMP-regulated
chloride channel (cystic ﬁbrosis transmembrane regulator,
CFTR). It was shown that PPARγ expression is altered in
tissue lacking CFTR. PPARγ expression in cftr-/- mice is
downregulatedattheRNAandproteinlevelsanditsfunction
diminished [70]. These changes may be related to the loss of
function of CFTR and may be relevant to the pathogenesis
of metabolic abnormalities associated with cystic ﬁbrosis.
Recently Nofziger et al. demonstrated that PPARγ agonists
inhibit vasopressin-mediated anion transport in the MDCK-
C7 cells. The PPARγ agonist-induced downregulation of
anion secretion is the result of decreased CFTR expression
and suggests a primary role for inhibition of CTRF in
the development of water and electrolyte imbalance during
PPARγ agonist therapy [71–73]. Similar TZD-mediated
eﬀectsonCl− ﬂuxhasbeendemonstratedinmouseintestinal
epithelia [74]. PPARγ agonists have been considered for
treatment of cystic ﬁbrosis on the basis of their anti-
inﬂammatory activities [75]. Importantly, Harmon and col-
leagues have recently established that additional parameters,
such as metabolites of AA should be considered in the
design of clinical trials [76]. Experimental studies have
shownthatcolonicepithelialcellsandwholelungtissuefrom
Cftr-deﬁcient mice show a defect in PPARγ function that
contributes to a pathological program of gene expression.
Lipidomic analysis suggests that this defect results in part
fromreducedamountsoftheendogenousPPARγ-ligand,15-
keto-prostaglandin E2.
6. Conclusions
Here we summarize the current knowledge of PPARγ-
dependent regulation of ENaC activity and ENaC-mediated
sodium reabsorption. This regulation is clearly not
completely understood and requires further studies.
Diﬀerences in these reported ﬁndings may be for example
due to the dose and time-course of treatment, species
or expression system, and/or the possibility that some
studies are examining total protein pools and others
mRNA levels. Even in vivo studies have their limitations.
Additional studies are required to sort out the exact
contribution of PPARγ to ENaC regulation. Figure 3
details a possible model for PPARγ regulation of epithelialPPAR Research 7
transport through ENaC-dependent and independent
mechanisms in the collecting duct. Thus, the exact
mechanism by which PPARγ agonists induce ﬂuid retention
is not completely clear but is likely to be multifactorial. It
is undoubted that ENaC is not the sole channel responsible
f o rﬂ u i dr e t e n t i o na n ds o d i u mr e a b s o r p t i o ni nr e s p o n s et o
PPARγ agonists. Other channels and transporters such as
NSC in IMCD, CFTR, Na-K-ATPase, NHE3, and NKCC are
most likely also involved in this process. However, a clear
account of these proteins in water-electrolyte homeostasis
during TZD therapy is still needed. Furthermore, a role
of PPARα agonists and RXR is also unclear and requires
additional studies.
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